 Mutagen sensitivity patients head neck cancers biologic marker risk multiple primary malignancies Eighty-four patients head neck cancers vitro sensitivity mutagens development multiple primary malignancies mutagen sensitivity lymphocytes vitro bleomycin-induced chromosomal breaks cell mutagen-hypersensitive patients ie break cell likely multiple primary cancers patients sensitive equal break cell relative risk confidence limits relationship independent age sex site treatment first primary cancer tobacco alcohol exposures Sensitivity bleomycin-induced chromosomal damage serves indicator genetic susceptibility primary malignancies patients head neck cancers